Organizers
Sven Rottenberg (NKI), Jos Jonkers (NKI),
Elisabetta Marangoni (Institut Curie), Virginie Dangles-Marie (Institut Curie)

Personalized cancer therapy requires detailed insight into the mechanisms underlying the response of individual tumors to (combinations of) targeted therapeutics and chemotherapy drugs. Understanding mechanisms of acquired therapy resistance is equally important since most patients with disseminated cancer eventually die due of tumors that are refractory to all available treatments.

This symposium will provide an overview of preclinical approaches aimed at understanding basic mechanisms of therapy response and resistance in order to improve personalized cancer therapy.

The emphasis of this course will be on the use of genetically engineered mouse models and patient-derived xenograft (PDX) models for in vivo preclinical research, but also in vitro preclinical assays employing established tumor cell lines and functional genomics approaches will be discussed.During the 3-day symposium national and international experts will present current approaches used in the field.

Poster presentation (voluntary)

Participants who want to discuss recent data with colleagues are invited to present a poster (A0, portrait format) during the symposium.

Please send an abstract to: preclinical.assays@nki.nl<mailto:preclinical.assays@nki.nl>.

The abstract should include title, list of authors, affiliation and a text body of 300 words maximum.

Registration and further information:
http://www.nki.nl/Research/Seminars/Events/Symposium+on+Preclinical+Assays+in+Cancer+Therapy.htm

Deadline for registration: August 15, 2012

Registration fee for the symposium:

EUR 450 for industry
EUR 300 for academics